These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20948453)

  • 81. Adjuvant properties of lipopolysaccharide from Neisseria meningitidis serogroup B detoxified and conjugated with tetanus toxoid.
    Balboa JA; Cuello M; Cabrera O; del Campo J; Lastre M; Gil D; Taboada C; Fariñas M; Hernández M; Pérez O
    Vaccine; 2006 Apr; 24 Suppl 2():S2-63-4. PubMed ID: 16823931
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Conjugation of meningococcal lipopolysaccharide R-type oligosaccharides to tetanus toxoid as route to a potential vaccine against group B Neisseria meningitidis.
    Jennings HJ; Lugowski C; Ashton FE
    Infect Immun; 1984 Jan; 43(1):407-12. PubMed ID: 6418661
    [TBL] [Abstract][Full Text] [Related]  

  • 83. New method for obtaining conjugated vaccines.
    Cabrera O; Cuello M; Soto CR; Martínez ME; del Campo JM; Pérez Oa; Infante JF; Sierra G
    Vaccine; 2006 Apr; 24 Suppl 2():S2-76-8. PubMed ID: 16823936
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Determining trace amounts and the origin of formaldehyde impurity in Neisseria meningitidis A/C/Y/W-135-DT conjugate vaccine formulated in isotonic aqueous 1× PBS by improved C18-UPLC method.
    Gudlavalleti SK; Crawford EN; Tran NN; Orten DJ; Harder JD; Reddy JR
    J Pharm Biomed Anal; 2015 Mar; 107():432-6. PubMed ID: 25668795
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Common Genetic Variations Associated with the Persistence of Immunity following Childhood Immunization.
    O'Connor D; Png E; Khor CC; Snape MD; Hill AVS; van der Klis F; Hoggart C; Levin M; Hibberd ML; Pollard AJ
    Cell Rep; 2019 Jun; 27(11):3241-3253.e4. PubMed ID: 31189108
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Tetanus toxoid loaded 'preformed microspheres' of cross-linked dextran.
    Diwan M; Khar RK; Talwar GP
    Vaccine; 2001 Jul; 19(28-29):3853-9. PubMed ID: 11427257
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Tetanus toxoid boosters.
    Rothstein RJ
    JAMA; 1978 Mar; 239(12):1133. PubMed ID: 146752
    [No Abstract]   [Full Text] [Related]  

  • 88. [Alopecia universalis in an adult after routine tetanus toxoid vaccine].
    Sánchez-Ramón S; Gil J; Cianchetta-Sívori M; Fernández-Cruz E
    Med Clin (Barc); 2011 Mar; 136(7):318. PubMed ID: 20451934
    [No Abstract]   [Full Text] [Related]  

  • 89. Conjugate vaccines and autism.
    Rose NR
    Med Hypotheses; 2011 Dec; 77(6):937-9. PubMed ID: 21907498
    [No Abstract]   [Full Text] [Related]  

  • 90. [Protective tetanus antibody titres and new re-vaccination requirements].
    Aboal Beato MÁ; Martínez Suárez M; Castrillón Piñeiro LM; Juncal Fondevila AR
    Aten Primaria; 2012 Feb; 44(2):e1-2. PubMed ID: 21397361
    [No Abstract]   [Full Text] [Related]  

  • 91. Allergy to tetanus toxoid vaccine.
    Bellioni Businco B; Paganelli R; Bruno G; Grossi O; Di Rienzo A; Businco L
    Allergy; 2001 Jul; 56(7):701-2. PubMed ID: 11421933
    [No Abstract]   [Full Text] [Related]  

  • 92. Adverse reactions to tetanus toxoid.
    Sutter RW
    JAMA; 1994 May; 271(20):1629. PubMed ID: 8182821
    [No Abstract]   [Full Text] [Related]  

  • 93. Recurrence of reactive arthritis after a booster dose of tetanus toxoid.
    Kaul A; Adler M; Alokaily F; Jawad AS
    Ann Rheum Dis; 2002 Feb; 61(2):185. PubMed ID: 11796415
    [No Abstract]   [Full Text] [Related]  

  • 94. Reactions after plain and adsorbed tetanus vaccines.
    White WG
    Lancet; 1980 Jan; 1(8158):42. PubMed ID: 6101378
    [No Abstract]   [Full Text] [Related]  

  • 95. Evaluating Functional Immunity Following Encapsulated Bacterial Infection and Vaccination.
    Toh ZQ; Higgins RA; Mazarakis N; Abbott E; Nathanielsz J; Balloch A; Mulholland K; Licciardi PV
    Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34203030
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Acute radiculomyelitis after antitetanus vaccination.
    Tezzon F; Tomelleri P; Ferrari G; Sergi A
    Ital J Neurol Sci; 1994 May; 15(4):191-3. PubMed ID: 7960672
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Safety of tetanus vaccination in relapsing-remitting multiple sclerosis.
    De Keyser J
    Infection; 1998; 26(5):319. PubMed ID: 9795797
    [No Abstract]   [Full Text] [Related]  

  • 98. [Spanish pharmacovigilance system of vaccines].
    Madurga M; Lázaro E; Montero D
    Med Clin (Barc); 2012 Feb; 138(2):86. PubMed ID: 22014846
    [No Abstract]   [Full Text] [Related]  

  • 99. Immunogenicity and safety of the Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants.
    Klein NP; Abu-Elyazeed R; Baine Y; Cheuvart B; Silerova M; Mesaros N
    Hum Vaccin Immunother; 2019; 15(2):327-338. PubMed ID: 30252603
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development.
    Dretler AW; Rouphael NG; Stephens DS
    Hum Vaccin Immunother; 2018 May; 14(5):1146-1160. PubMed ID: 29543582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.